Navigation Links
Cardiac Science and Gust Bardy, MD Create Innovation Center for Primary Care Medicine

BOTHELL, Wash., Jan. 11 /PRNewswire-FirstCall/ -- Cardiac Science Corporation (Nasdaq: CSCX), a global leader in automated external defibrillator (AED) and diagnostic cardiac monitoring devices, has joined with Gust Bardy, MD to create an innovation center focused on the development and commercialization of simple, cost-effective medical products and services that positively impact public health.


"Dr. Bardy shares our vision for the future of medicine and the growing importance of primary, remote, and self-directed care," said Dave Marver, Cardiac Science president and chief executive officer. "He is a proven thought-leader, researcher, clinician, and entrepreneur. We are pleased to forge this long-term relationship with Dr. Bardy to drive innovation and create value."

Under the agreement, Dr. Bardy will lead the Innovation Center within Cardiac Science to develop and commercialize advancements in medical technology and services. The Innovation Center will join Cardiac Science resources with Dr. Bardy's network of physician and research colleagues to focus on novel developments that simplify patient care with improved outcomes.

Dr. Bardy currently leads the Seattle Institute for Cardiovascular Research, where he served as Director and Primary Investigator for several significant trials in cardiology, including the Sudden Cardiac Death in Heart Failure Trial (SCD-HeFT) and the Home AED Trial (HAT). He is also founder and board member of Cameron Health, Inc. and is clinical professor of medicine in cardiology and cardiac electrophysiology at University of Washington. Dr. Bardy has obtained more than 350 patents worldwide.

"With their broad reach into primary care and general cardiology offices, Cardiac Science is an ideal partner. I am passionate about making it easier for patients to access medical care and effectively navigate the healthcare system," said Gust Bardy, MD. "Dave and the team at Cardiac Science embrace change. I'm excited to be working with them and look forward to bringing many new ideas to physicians and their patients."

About Cardiac Science:

Cardiac Science develops, manufactures, and markets a family of advanced diagnostic and therapeutic cardiology devices and systems, including automated external defibrillators (AED), electrocardiograph devices (ECG/EKG), cardiac stress test treadmills and systems, Holter monitoring systems, hospital defibrillators, cardiac rehabilitation telemetry systems, vital signs monitors, and cardiology data management systems (informatics) that connect with hospital information (HIS), electronic medical record (EMR), and other information systems. The company sells a variety of related products and consumables and provides a portfolio of training, maintenance, and support services. Cardiac Science, the successor to the cardiac businesses that established the trusted Burdick®, HeartCentrix®, Powerheart®, and Quinton® brands, is headquartered in Bothell, Washington. With customers in more than 100 countries worldwide, the company has operations in North America, Europe, and Asia. For information, call 425.402.2000 or visit

For updates and information on worldwide defibrillation and cardiac monitoring, find us on the Cardiac Science blog at, Twitter at, Facebook at, YouTube at

Forward-Looking Statements

This press release contains forward-looking statements. The words "believe," "expect," "intend," "anticipate," variations of such words, and similar expressions identify forward-looking statements, but their absence does not mean that the statement is not forward-looking. Forward-looking statements in this press release include, but are not limited to, those relating to the potential impact of the affiliation with Dr. Bardy on Cardiac Science Corporation's growth strategies and the resulting impact on operating results. These are forward-looking statements for purposes of the safe harbor provisions under the Private Securities Litigation Reform Act of 1995. Actual results may vary significantly from the results expressed or implied in such statements. Factors that could cause or contribute to such varying results and other risks are more fully described in Cardiac Science Corporation's Annual Report on Form 10-K for the year ended December 31, 2008, as updated by subsequent quarterly reports on Form 10-Q. Cardiac Science Corporation undertakes no duty or obligation to update the information provided herein.

For more information,

    Company Contact:              Investor Contact:   Media Contact:
    ----------------              -----------------   --------------
    Mike Matysik                  Matt Clawson        Christopher Gale
    Cardiac Science Corporation   Allen & Caron       EVC Group Inc.
    Senior Vice President and CFO 949.474.4300        646.201.5431
    425.402.2009         203.570.4681


SOURCE Cardiac Science Corporation
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. NewCardio to Sponsor and Present at 4th Annual Cardiac Safety Assessment Summit
2. Reportlinker Adds Cardiac Biomarkers - A Global Market Perspective
3. Inability of Pixantrone to Form Toxic Iron Complexes Results in Significant Reduction in Cardiac Cell Toxicity Compared to Currently Marketed Anthracyclines
4. Reportlinker Adds Cardiac Pacemakers - A World Market Analysis
5. Reportlinker Adds Cardiac Defibrillators - A Worldwide Market Intelligence Report
6. Poniard Pharmaceuticals Announces Updated Positive Clinical Data from Phase 2 Trial of Picoplatin in Colorectal Cancer and New Phase 1 Cardiac Safety Trial Results
7. American Heart Association Late-Breaking Clinical Trial Report: New Reversible Oral Drug Reduces Cardiac Events in Primary PCI Patients
8. Cardiac Science Appoints Peter Kingma Senior Vice President Sales and Marketing
9. Cardiac Science Announces Third Quarter Results
10. Boston Scientifics Most Advanced Devices to Treat Heart Failure and Sudden Cardiac Death Now Available in Japan
11. PAREXEL Enhances Early Phase Cardiac Safety Capabilities Through Alliance With Mortara Instrument
Post Your Comments:
(Date:11/26/2015)... STOCKHOLM , November 26, 2015 ... the potential to use SyMRI to find optimal contrast weighting ... brain tumor metastases, and has signed a research agreement with ... at the hospital. Using SyMRI, it is possible to generate ... parameter settings after the patient has left, thus making it ...
(Date:11/26/2015)... 2015 ) ... "2016 Future Horizons and Growth Strategies in ... Supplier Shares, Country Segment Forecasts, Competitive Intelligence, ... --> ) has announced ... Horizons and Growth Strategies in the French ...
(Date:11/26/2015)... DUBLIN , Nov. 26, 2015 Research ... of the "Advanced Wound Care Market by Type ... Ulcers), End User (In-Patient Facility, Out-Patient Facility), and Geography ... offering. --> --> ... the description, definition and forecast of the global advanced ...
Breaking Medicine Technology:
(Date:11/27/2015)... (PRWEB) , ... November 27, 2015 , ... ... a safe and convenient way to dispense prescription medications at home, so he ... effective way to monitor and dispense prescription medications. In doing so, it could ...
(Date:11/27/2015)... ... , ... MPWH, the No.1 Herpes-only dating community in the world, revealed that over 50% of ... than 3.7 billion people under the age of 50 – or 67% of the population ... global estimates of HSV-1 infection . , "The data shocks us highly!" said Michelle ...
(Date:11/27/2015)... , ... November 27, 2015 , ... ... an innovative online platform for mental health and wellness consultation, has collaborated with ... partnership will bridge the knowledge gap experienced by parents and bring advice from ...
(Date:11/27/2015)... ... 27, 2015 , ... Indosoft Inc., developer and distributor of ... 11 LTS (Long Term Support) into its Q-Suite 5.10 product line. , Making ... with a version of Asterisk that will receive not only security fixes, but ...
(Date:11/26/2015)... ... ... The Catalent Applied Drug Delivery Institute today announced a ... selection in early phase drug development. The first of these is to be ... UK’s emerging life sciences companies, corporate partners, and investors, at Milton Park, Oxford, ...
Breaking Medicine News(10 mins):